Navigation Links
Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
Date:8/8/2012

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of Andrew J. McKnight, Ph.D. as Senior Director, Target Biology.  Dr. McKnight comes to AnaptysBio with extensive experience in the design and development of novel therapeutic antibodies across a variety of therapeutic areas.  Working together with David J. King, Ph.D., AnaptysBio's chief scientific officer, Dr. McKnight will be leading the advancement of AnaptysBio's current and future internal pipeline programs. 

(Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

AnaptysBio's primary objective is the advancement of novel therapeutic antibody programs generated using the Company's proprietary SHM-XEL platform.  As the first company to replicate somatic hypermutation (SHM) in vitro for antibody discovery, AnaptysBio's SHM-XEL platform is uniquely positioned to generate therapeutic antibodies with unique functionality.  The Company is currently pursuing differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders and antibody-drug conjugate applications.  AnaptysBio's internal programs are independent of the Company's partnerships with Merck, Roche, Novartis, Celgene, Gilead and DARPA. 

Dr. McKnight comes to AnaptysBio most recently from Pfizer's Biotherapeutics group, where he directed numerous internal and partnered antibody development projects.  Prior to Pfizer, Dr. McKnight led antibody projects at UCB-Celltech. Dr. McKnight received his doctorate from University of Oxford and was a postdoctoral fellow at Harvard Medical School. 

"We are delighted to add Andrew's target biology experience to AnaptysBio's research and development team," said Hamza Suria, AnaptysBio's president and chief executive officer. "The unique strengths of our SHM-XEL platform provide AnaptysBio with distinct advantages in the design and discovery of novel therapeutic antibodies."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. SHM is the body's natural process for generating potent antibodies.  AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, functionality, cross-reactivity and epitope diversity.   AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene and Gilead.  Major investors in AnaptysBio include founding investor Avalon Ventures, as well as Alloy Ventures, Frazier Healthcare Ventures, and Novo A/S. For more information, visit www.anaptysbio.com.


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asthmapolis Expands Dignity Health Study to Include Mercy Medical Group Patients
2. Hospira Expands Board of Directors With Election of Dennis M. Fenton
3. The MED Group Expands MED Suppliers Network to add Ventilator Program
4. Integrity Life Sciences Expands Orthotic Options for Domestic and International Customers
5. Practice Fusion Expands Executive Team with Addition of General Counsel and Associate VP of Corporate Development
6. OceanGate Inc. Expands Board of Directors with Two Key Appointments
7. ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment
8. Acquisition of Navigenics Expands Life Technologies Capabilities in Diagnostics
9. Echo Therapeutics Expands License Agreement with Ferndale Pharma
10. Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals
11. Dr. Jills Foot Pads Secures GSA Schedule and Expands to Service VA and Federal Agencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... AVIV, Israel , March 27, 2017 ... on oncology and immunology, announced today that AGI-134, an immunotherapy ... announced acquisition of Agalimmune Ltd., will be featured at the ... in Washington, DC to be ... ...
(Date:3/27/2017)... March 27, 2017   Pulmatrix, Inc . (NASDAQ: PULM), ... address serious pulmonary diseases, today announced that it has added ... fibrosis and asthma to its Scientific Advisory Board . ... Richard B. Moss , MD, former chief of the ... Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017  BERG, a ... data-driven, biological research approach, today announced that ... the discovery of new data using a ... brown fat metabolism. Joslin Diabetes Center led ... Biology® platform for analysis of samples.  The ...
Breaking Medicine Technology:
(Date:3/28/2017)... ORANGE, Calif. (PRWEB) , ... March 28, 2017 ... ... of its leading physicians, Paul Yost, will begin serving as new board chair ... earlier this month. Yost will serve the remainder of soon-to-be former chair Mark ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ongoing effort ... has recently developed and published an informational resource that addresses frequently asked questions. ... common inquiries the site’s team of third party administrator (TPA) contributors regularly receives ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... ... common and unwelcomed occurrence in people of all ages, genders and ethnicities. Dermatologist Dr. Sonoa ... dealing with excess skin oil. “Oily skin is a challenge to many of my patients. ... oily shine while keeping the skin fresh and clean,” says Dr. Au. , What causes ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have ... sleep apnea treatment, with or without a referral. Sleep apnea is often left untreated ... daytime sleepiness, morning headaches and chronic snoring. , Dr. Braasch seeks to raise ...
Breaking Medicine News(10 mins):